Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
MNPR
MNPR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MNPR News
Monopar Releases New Analysis Data on ALXN1840
1d ago
Newsfilter
Monopar Therapeutics Reports Q4 Earnings Miss
Mar 27 2026
seekingalpha
Monopar Reports 2025 Financial Results and Drug Development Updates
Mar 27 2026
Newsfilter
MONOPAR RELEASES FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2025 ALONG WITH BUSINESS UPDATE
Mar 27 2026
moomoo
Goldman Sachs Cuts Netflix Price Target to $112 Ahead of Earnings
Jan 09 2026
CNBC
Biotech Stocks Surge at Year-End 2025, ETFs Gain 35.84%
Dec 31 2025
Benzinga
Monopar CFO Vu Acquires 1,500 Shares of MNPR for $104,925
Dec 29 2025
NASDAQ.COM
Home Depot Analyst Changes Stance; Check Out the Top 5 Downgrades for Friday
Nov 14 2025
Benzinga
Chardan Capital Reaffirms Buy Rating on Monopar Therapeutics with $100 Price Target Intact
Nov 13 2025
Benzinga
Chardan Capital Reaffirms Buy Rating on Monopar Therapeutics and Increases Price Target to $100
Nov 10 2025
Benzinga
Monopar Unveils New Findings on Enhanced Copper Balance in Wilson Disease Patients Treated with Tiomolybdate Choline at AASLD - The Liver Meeting® 2025
Nov 09 2025
Newsfilter
Oppenheimer Upgrades Monopar Therapeutics to Outperform, Increases Price Target to $115
Oct 02 2025
Benzinga
Piper Sandler Keeps Overweight Rating on Monopar Therapeutics and Increases Price Target to $95
Sep 25 2025
Benzinga
CrowdStrike Set to Surge by 26%? Check Out 10 Leading Analyst Predictions for Thursday
Sep 25 2025
Benzinga
BTIG Reaffirms Buy Rating for Monopar Therapeutics, Increases Price Target to $104
Sep 25 2025
Benzinga
Chardan Capital Reaffirms Buy Rating on Monopar Therapeutics and Increases Price Target to $85
Sep 25 2025
Benzinga
Show More News
